Bright Minds Biosciences Inc. - common stock (OQ:DRUG)
Business Focus: N/A
Dec 06, 2023 04:08 pm ET
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Nov 22, 2023 08:31 am ET
Thinking about trading options or stock in Medtronic, Applied Materials, Autolus Therapeutics, Bright Minds Biosciences, or Tremor International?
NEW YORK, Nov. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDT, AMAT, AUTL, DRUG, and TRMR.
Aug 08, 2023 06:50 am ET
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced...
Jul 20, 2023 06:50 am ET
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced...
Jul 18, 2023 09:31 am ET
Thinking about buying stock in Livent, Bitfarms, Altus Power, Bright Minds Biosciences, or CEL-SCI Corp?
NEW YORK, July 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LTHM, BITF, AMPS, DRUG, and CVM.
Jul 14, 2023 09:31 am ET
Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences?
NEW YORK, July 14, 2023 InvestorsObserver issues critical PriceWatch Alerts for MNMD, OPK, GRR, HYZN, and DRUG.
Jul 11, 2023 06:50 am ET
Bright Minds Announces Effective Date of Share Consolidation
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that,...
Jun 22, 2023 06:50 am ET
Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it...
Apr 19, 2023 06:50 am ET
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that...
Apr 10, 2023 06:50 am ET
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that...
Feb 27, 2023 06:50 am ET
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an...
Feb 17, 2023 06:50 am ET
Bright Minds Biosciences Announces Non-Executive Director Appointment
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the...
Feb 08, 2023 04:05 pm ET
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following...
Jan 27, 2023 04:05 pm ET
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying...
Jan 09, 2023 04:05 pm ET
Bright Minds Biosciences Announces Resignation of Board Member
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Dec 02, 2022 07:06 pm ET
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded...
Nov 28, 2022 06:50 am ET
Bright Minds Biosciences Announces Non-Brokered Private Placement
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered private placement of (i) pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”),...
Nov 23, 2022 11:35 am ET
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Oct 18, 2022 09:31 am ET
Thinking about buying stock in Akouos, Federated National, Bright Minds Biosciences, VNET Group, or MFA Financial?
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKUS, FNHC, DRUG, VNET, and MFA.
Sep 07, 2022 06:50 am ET
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Aug 31, 2022 06:50 am ET
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Aug 30, 2022 03:35 pm ET
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) of 2,858,000 units of the Company at a price of...
Aug 26, 2022 09:31 am ET
Thinking about buying stock in Bright Minds Biosciences, Futu Holdings, Zhihu, Tencent Music Entertainment, or IQIYI?
NEW YORK, Aug. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRUG, FUTU, ZH, TME, and IQ.
Aug 25, 2022 10:45 am ET
Thinking about buying stock in Bright Minds Biosciences, Kiora Pharmaceuticals, FuelCell Energy, Athersys, or Minerva Neurosciences?
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRUG, KPRX, FCEL, ATHX, and NERV.
Aug 24, 2022 08:30 am ET
Thinking about buying stock in Bed Bath & Beyond, Bright Minds Biosciences, Farfetch, SoFi Technologies, or Minerva Neurosciences?
NEW YORK, Aug. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBBY, DRUG, FTCH, SOFI, and NERV.
Aug 23, 2022 09:06 pm ET
Bright Minds Announces Pricing of Overnight Marketed Offering of Units
Bright Minds Biosciences Inc. (“Bright Minds” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is pleased to announce...
Aug 18, 2022 03:33 pm ET
Bright Minds Biosciences Comments on Recent Trading Activity
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news...
Jun 27, 2022 06:50 am ET
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
May 12, 2022 06:50 am ET
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
May 02, 2022 06:50 am ET
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Apr 19, 2022 06:50 am ET
Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Mar 14, 2022 06:50 am ET
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Mar 08, 2022 07:30 am ET
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Jan 04, 2022 04:05 pm ET
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Dec 06, 2021 06:50 am ET
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced...
Nov 30, 2021 07:30 am ET
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided a...
Nov 03, 2021 06:50 am ET
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.